As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Oxford BioDynamics ( ($GB:OBD) ) just unveiled an announcement. Oxford BioDynamics Plc announced it will release its financial results for the ...

Highly valued economically, ecologically and culturally, the white oak (Quercus alba) is a keystone forest species and is one ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News Commentary - Amid the excitement surrounding ...

NeoGenomics reported mixed results for the fourth quarter. While it beat on earnings (after adjustments), it missed on ...

A cohort of academic theme leads has been appointed to strengthen transatlantic ties through new convergence science and ...

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. See why I think ...

HKGI Partners with Global Leaders to Chart a Course for Healthcare Transformation HONG KONG, /PRNewswire/ -- Genomic medicine has been gaining global prominence for its vast potential to ...

Usually, ‘What happens in Vegas, stays in Vegas’, is the prevailing moto of Sin City, but that is certainly not the case for ...

ST. LOUIS - Scientists around St. Louis worry their medical research will lose key funding as the National Institutes of ...

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.